Gonadotropins — the injectable fertility hormones sold under names like Gonal-F, Follistim, and Menopur — produce more twins than any other fertility drug on the market. According to the American Society for Reproductive Medicine, up to 30 percent of pregnancies resulting from gonadotropin treatment are multiples, with as many as 5 percent being triplets or higher-order births. That is a staggering 1-in-3 chance of carrying more than one baby, a rate that dwarfs the roughly 1.25 percent twin rate seen in natural conception. For families navigating fertility treatment, this statistic carries real weight.
A couple undergoing injectable gonadotropin therapy for unexplained infertility, for instance, may walk into treatment hoping for one healthy pregnancy and walk out carrying twins — a outcome that changes everything from prenatal care to long-term financial planning. The implications extend beyond obstetrics, too. Research increasingly connects the physical and cognitive demands of raising multiples, as well as the pregnancy complications that often accompany twin gestations, to maternal brain health outcomes that matter well into later life. This article breaks down why gonadotropins sit at the top of the twin-rate hierarchy, how they compare to oral fertility drugs like Clomid and letrozole, what the latest national statistics tell us about multiple births in the United States, and what physicians and professional organizations recommend to manage the risks.
Table of Contents
- Why Do Gonadotropins Cause More Twins Than Any Other Fertility Drug?
- How Gonadotropin Twin Rates Compare to Clomid, Letrozole, and IVF
- The National Scale of Fertility-Drug Multiples in the United States
- What Physicians Recommend to Reduce Multiple Pregnancy Risk
- Cognitive and Brain Health Implications of Twin Pregnancies
- The Emotional and Practical Realities of Unexpected Twins
- Where Fertility Medicine Is Headed on Multiple Birth Prevention
- Conclusion
- Frequently Asked Questions
Why Do Gonadotropins Cause More Twins Than Any Other Fertility Drug?
The answer comes down to how these drugs interact with the ovaries. Oral fertility medications like clomiphene citrate and letrozole work indirectly — they signal the brain to release more follicle-stimulating hormone, and the body’s natural feedback mechanisms still exert some control over how many egg follicles develop. Gonadotropins skip that entire regulatory system. They deliver FSH and LH directly into the bloodstream, flooding the ovaries with stimulation that the brain’s pituitary gland would never produce on its own. The result is that multiple follicles mature simultaneously, each one capable of releasing a viable egg. Physicians try to manage this with ultrasound monitoring and careful dose adjustments throughout a treatment cycle.
But the multi-follicle response to gonadotropins remains inherently less predictable than what happens with oral medications. A woman might develop two mature follicles one cycle and five the next on the same dose. When several eggs release during ovulation, the odds of two or more being fertilized climb sharply. This is why nearly all fertility-drug twins are fraternal, or dizygotic — they come from separate eggs fertilized by separate sperm, not from a single embryo splitting. By comparison, clomiphene citrate produces a twin rate of roughly 5 to 12 percent, and a recent systematic review published in PubMed in 2021 found that the contemporary multiple pregnancy rate with single-agent clomiphene under current prescribing guidelines has dropped to about 3.8 percent — 3.6 percent twins and just 0.2 percent triplets. That is a fraction of what gonadotropins produce.
How Gonadotropin Twin Rates Compare to Clomid, Letrozole, and IVF
The differences between fertility treatments are not subtle. Gonadotropins carry an approximately 30 percent multiple pregnancy rate. Clomiphene citrate falls in the 5 to 12 percent range historically, though more recent data suggests rates closer to 3.8 percent with modern monitoring protocols. Letrozole, increasingly favored as a first-line ovulation induction agent, produces an even lower twin rate of roughly 3.4 to 4.7 percent. A study published in Fertility and Sterility examining 16,001 intrauterine insemination cycles found twins in 4.7 percent of letrozole pregnancies compared to 7.5 percent with clomiphene — making letrozole roughly half as likely to produce multiples. IVF with single embryo transfer has the lowest multiple pregnancy rate among assisted reproductive technologies, at around 3 percent.
this may seem counterintuitive, since IVF is the most intensive fertility intervention. But the ability to transfer exactly one embryo gives clinicians a degree of control over multiple pregnancy risk that simply does not exist with ovulation-inducing drugs, where you cannot dictate how many eggs the ovaries will release. However, these comparisons come with a critical caveat. Lower twin rates do not necessarily mean a drug is the right choice for every patient. Gonadotropins are typically prescribed when oral medications have failed or when a woman’s diagnosis calls for more aggressive ovarian stimulation. A patient with diminished ovarian reserve, for example, may not respond adequately to letrozole alone, making the higher multiple-pregnancy risk of gonadotropins a calculated tradeoff rather than a reckless gamble.
The National Scale of Fertility-Drug Multiples in the United States
The impact of fertility drugs on twin and triplet births is not an abstract clinical concern — it has reshaped national birth statistics over decades. A landmark 2013 study published in the new England Journal of Medicine found that 36 percent of all twin births and a remarkable 77 percent of triplet and higher-order births in the United States resulted from fertility treatments. As NPR reported on that study, fertility drugs — not IVF — were the primary driver of multiple births in the country. The U.S. twin birth rate has increased more than 75 percent since 1980, a rise that tracks closely with the growing use of fertility medications and assisted reproduction.
According to the CDC’s National Vital Statistics Reports published in March 2025, the twin birth rate stood at 30.7 per 1,000 births in 2023, down 2 percent from the 2022 rate of 31.2. That modest decline reflects growing adoption of single embryo transfer in IVF and more conservative ovulation induction protocols, but the rate remains far above the natural baseline. For families affected, the consequences extend across a lifetime. Twin pregnancies carry elevated risks of preterm birth, low birth weight, gestational diabetes, and preeclampsia. Preeclampsia in particular has drawn attention from neurologists and dementia researchers, as studies have linked a history of the condition to increased risk of vascular cognitive impairment and dementia later in life. The maternal brain health implications of fertility-treatment complications are an area of growing scientific interest.
What Physicians Recommend to Reduce Multiple Pregnancy Risk
The American Society for Reproductive Medicine classifies multiple pregnancy as the single most common complication of fertility treatment. Their guidance is clear: when IVF is used, single embryo transfer should be the default to minimize the chance of twins or higher-order multiples. But for patients using gonadotropins outside of IVF — typically in combination with timed intercourse or intrauterine insemination — the calculus is more complex. Clinicians monitor gonadotropin cycles with transvaginal ultrasound and blood estradiol levels to track how many follicles are developing. If too many mature follicles appear, the physician may recommend canceling the cycle — meaning the couple forgoes the treatment that month rather than risk a high-order multiple pregnancy.
This is a genuinely difficult conversation in fertility medicine. Patients who have spent months or years trying to conceive, and who are paying thousands of dollars per cycle, are understandably reluctant to walk away from a cycle that might work. The tradeoff is real. Proceeding with three or four mature follicles increases the chance of pregnancy but also raises the probability of triplets or quadruplets, which carry substantially higher maternal and fetal risks than a singleton or even a twin pregnancy. Some clinics have moved toward lower-dose gonadotropin protocols — sometimes called “mini-stim” or “low-dose step-up” approaches — that aim to produce fewer follicles while still improving on what oral medications can achieve. These protocols reduce but do not eliminate the elevated multiple pregnancy rate.
Cognitive and Brain Health Implications of Twin Pregnancies
The connection between fertility treatments, multiple pregnancies, and long-term brain health is one that deserves more attention than it typically receives. Twin pregnancies place greater physiological stress on the maternal body, including higher rates of hypertensive disorders like preeclampsia and gestational hypertension. A growing body of evidence suggests that women who experience preeclampsia face elevated risk of cerebrovascular disease, white matter lesions, and cognitive decline in the decades following pregnancy. A 2018 meta-analysis found that women with a history of preeclampsia had roughly double the risk of vascular dementia compared to women with normotensive pregnancies.
Since twin gestations increase preeclampsia risk by two to three times compared to singletons, the chain from fertility drugs to multiple pregnancy to hypertensive complications to long-term cognitive vulnerability is a plausible pathway that researchers are still working to fully characterize. This does not mean that every woman who conceives twins through gonadotropin therapy will face cognitive problems later in life. The vast majority will not. But it does mean that the long-term health monitoring of women who experienced complicated twin pregnancies should include attention to cardiovascular and cognitive health — not just in the postpartum period, but across the lifespan. This is an area where reproductive medicine and brain health research are beginning to converge in important ways.
The Emotional and Practical Realities of Unexpected Twins
For many families, learning they are expecting twins after fertility treatment brings a complex mix of joy and anxiety. A woman who spent two years trying to conceive with her partner, finally turning to gonadotropin injections after clomiphene failed, may feel grateful and overwhelmed in the same breath when the first ultrasound reveals two heartbeats.
The financial reality is immediate — estimates suggest raising twins costs roughly 1.5 to 2 times more than raising a single child through the first five years, and that does not account for the higher likelihood of NICU stays if the babies arrive early. The sleep deprivation and physical demands of caring for twin newborns also carry cognitive implications that are relevant to brain health. Chronic sleep disruption in the postpartum period has been associated with impaired memory consolidation and increased inflammation, both of which are risk factors that brain health researchers track in the context of long-term cognitive resilience.
Where Fertility Medicine Is Headed on Multiple Birth Prevention
The trend in reproductive medicine is unmistakably toward reducing multiple pregnancies. Advances in embryo selection through preimplantation genetic testing have made single embryo transfer in IVF increasingly effective, pushing the field’s twin rate steadily downward. For gonadotropin cycles outside of IVF, research into biomarkers that better predict ovarian response — including anti-Müllerian hormone levels and antral follicle counts — is helping clinicians personalize dosing to minimize the multi-follicle outcomes that lead to twins and triplets.
Still, as long as gonadotropins remain a mainstay of fertility treatment for patients who need more than oral medications can offer, the elevated twin rate will persist. The 2023 CDC data showing the twin birth rate at 30.7 per 1,000 births suggests that progress is being made, but slowly. For patients, the most important step remains an honest conversation with their reproductive endocrinologist about the specific risks of their protocol and a clear plan for what happens if monitoring reveals too many developing follicles.
Conclusion
Gonadotropins stand apart from every other fertility drug in their capacity to produce twin pregnancies, with a multiple birth rate approaching 30 percent — roughly six times higher than clomiphene and eight times higher than letrozole. This is a direct consequence of how these injectable hormones work: bypassing the brain’s natural regulatory feedback and stimulating the ovaries to develop multiple follicles simultaneously. While oral fertility drugs and single embryo transfer in IVF have seen their twin rates decline under modern protocols, gonadotropins remain inherently harder to control.
For anyone considering fertility treatment, understanding these differences is essential to making informed decisions. The ASRM’s recommendation to treat multiple pregnancy as a serious complication — not a bonus outcome — reflects decades of evidence about the maternal and neonatal risks involved. Those risks, including the emerging connections between pregnancy complications and long-term cognitive health, underscore why every fertility treatment decision should be made with full awareness of what the numbers actually show.
Frequently Asked Questions
Which fertility drug has the highest twin rate?
Gonadotropins, the injectable FSH/LH hormones sold as Gonal-F, Follistim, and Menopur, produce the highest twin rate of any fertility drug — up to 30 percent of resulting pregnancies are multiples, according to the American Society for Reproductive Medicine.
What is the twin rate with Clomid compared to gonadotropins?
Clomid historically produces a 5 to 12 percent twin rate, though a 2021 systematic review found the contemporary rate under current guidelines is approximately 3.8 percent. Gonadotropins produce roughly 30 percent multiples — several times higher.
Does letrozole cause fewer twins than Clomid?
Yes. A Fertility and Sterility study of over 16,000 IUI cycles found twins in 4.7 percent of letrozole pregnancies versus 7.5 percent with clomiphene, making letrozole roughly half as likely to result in twins.
Are fertility drug twins identical or fraternal?
The vast majority are fraternal, or dizygotic. Fertility drugs work by stimulating the release of multiple eggs, each of which can be fertilized independently. Identical twins result from a single embryo splitting, which is not directly caused by fertility medications.
Can doctors prevent twins during gonadotropin treatment?
Physicians monitor cycles with ultrasound and blood work, and may recommend canceling a cycle if too many follicles develop. Low-dose protocols also help, but the multi-follicle response to gonadotropins remains inherently less predictable than with oral medications.
How much has fertility treatment contributed to the rise in twins nationally?
A 2013 New England Journal of Medicine study found that 36 percent of all twin births and 77 percent of triplet and higher-order births in the United States resulted from fertility treatments. The U.S. twin birth rate has risen more than 75 percent since 1980.
